Merck Sharp + Dohme Corp.

Angex Pharmaceutical, Inc.

Zhiqiang Yang

Craig William Lindsley

Scott D Kuduk

Ravi P Nargund

Anandan Palani

James C Barrow

Wen-Lian Wu

Steven D Young

Douglas C Beshore

Philippe G Nantermet

Subharekha Raghavan

Guizhen Dong

Francis Lee

Raphaelle Berger

John Qiang Tan

Milana M Maletic

Olga Ornoski

Songnian Lin

Lin Yan

Jianmin Fu

Brian T Campbell

Sandra Lee Knowles

William D Shipe

Joie Garfunkle

Pei Huo

Dann LeRoy Parker, Jr

Fengqi Zhang

Libo Xu

Keith P Moore

Youheng Shu

Alan Whitehead

Alexander J Kim

Gang Ji

David Wisnoski

Falong Jiang

Constantine Kreatsoulas

Evan Foster Shalen

Dann L Parker

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Carbamate and urea compounds as multikinase inhibitors

The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

Cyclic compounds as immunomodulating agents

The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

Macrocyclic compounds as TRK kinase inhibitors and uses thereof

Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

Insulin dimer-incretin conjugates

Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R, R, R, R, and Rare as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy. 

Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, R, R, R, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose. 

Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators

The present invention relates to bicyclic himbacine derivatives of the formula   and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof. 

Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators

The present invention relates to bicyclic himbacine derivatives of the formula  and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists

Growing community of inventors

Westfield, NJ, United States of America

Zhiqiang Yang